Show simple item record

dc.contributor.authorO'Connor, Anthony
dc.contributor.authorGisbert, Javier P
dc.contributor.authorMcNamara, Deirdre
dc.contributor.authorO'Morain, Colm
dc.date.accessioned2012-02-01T10:48:42Z
dc.date.available2012-02-01T10:48:42Z
dc.date.issued2012-02-01T10:48:42Z
dc.identifier.citationHelicobacter. 2010 Sep;15 Suppl 1:46-52. doi: 10.1111/j.1523-5378.2010.00774.x.en_GB
dc.identifier.issn1523-5378 (Electronic)en_GB
dc.identifier.issn1083-4389 (Linking)en_GB
dc.identifier.pmid21054653en_GB
dc.identifier.doi10.1111/j.1523-5378.2010.00774.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207869
dc.description.abstractIt is accepted that the success of Helicobacter pylori eradication treatment using standard triple therapy is declining. Resistance, particularly to clarithromycin, has been shown in numerous countries to be rising to a level where the use of standard triple therapy in its current form may no longer be justified. The two major factors influencing resistance are prior exposure to the antibiotic and compliance with therapy. Regimes based on bismuth and levofloxacin, which had previously been mainly second-line options, are now emerging as superior first-line options. Trials of sequential and concomitant therapies are also showing the usefulness of these treatments in different populations. Options for third and subsequent line therapies include furazolidone and rifabutin-based regimes. Susceptibility testing should be performed to maintain accurate data on resistance levels, and has also clinical utility in difficult to eradicate cases. None of these, however, will be successful unless compliance is improved upon. If compliance is assured and eradication confirmation pursued, it has been repeatedly illustrated that near full eradication is achievable.
dc.language.isoengen_GB
dc.subject.meshAnti-Bacterial Agents/pharmacology/*therapeutic useen_GB
dc.subject.meshBismuth/therapeutic useen_GB
dc.subject.mesh*Drug Resistance, Bacterialen_GB
dc.subject.meshHelicobacter Infections/*drug therapyen_GB
dc.subject.meshHelicobacter pylori/*drug effectsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMedication Adherenceen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleTreatment of Helicobacter pylori infection 2010.en_GB
dc.contributor.departmentDepartment of Gastroenterology, Adelaide and Meath Hospital incorporating the, National Children's Hospital/Trinity College Dublin, Tallaght, Dublin 24,, Ireland. oconna12@tcd.ieen_GB
dc.identifier.journalHelicobacteren_GB
dc.description.provinceLeinster
html.description.abstractIt is accepted that the success of Helicobacter pylori eradication treatment using standard triple therapy is declining. Resistance, particularly to clarithromycin, has been shown in numerous countries to be rising to a level where the use of standard triple therapy in its current form may no longer be justified. The two major factors influencing resistance are prior exposure to the antibiotic and compliance with therapy. Regimes based on bismuth and levofloxacin, which had previously been mainly second-line options, are now emerging as superior first-line options. Trials of sequential and concomitant therapies are also showing the usefulness of these treatments in different populations. Options for third and subsequent line therapies include furazolidone and rifabutin-based regimes. Susceptibility testing should be performed to maintain accurate data on resistance levels, and has also clinical utility in difficult to eradicate cases. None of these, however, will be successful unless compliance is improved upon. If compliance is assured and eradication confirmation pursued, it has been repeatedly illustrated that near full eradication is achievable.


This item appears in the following Collection(s)

Show simple item record